<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02968342</url>
  </required_header>
  <id_info>
    <org_study_id>18.11.2015-21/35</org_study_id>
    <nct_id>NCT02968342</nct_id>
  </id_info>
  <brief_title>Role of Progesterone in Hypoactive Sexual Desire Disorder in Menopausal Women</brief_title>
  <official_title>Role of Progesterone in Hypoactive Sexual Desire Disorder in Menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bezmialem Vakif University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bezmialem Vakif University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is the role of vaginal progesterone gel in the treatment of
      menopausal hypoactive sexual desire disorder. Half of the study participants will receive a
      standard dose of self applied vaginal progesterone gel and the other half will receive oral
      vitamin tablets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Steroid hormones play fundamental roles in sexual behaviour. Sexual activity is related to
      hormone concentrations and ovulation in women. Women's sexuality, unlike that of most
      mammals, is not solely defined by sexual receptivity during the short window of fertility.
      Women are also prone to initiate luteal-phase sex when serum levels of progesterone are
      highest in the menstrual cycle.As a result of ovarian hormonal cessation after menopause
      women may face alterations in sexual desire.

      The role of progesterone supplementation in improving sexual desire in the menopausal period
      is investigated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FSFI (Female Sexual Function Index) questionnaire &quot;arousal&quot; domain</measure>
    <time_frame>1 month</time_frame>
    <description>Increment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FSFI (Female Sexual Function Index) questionnaire &quot;lubrication&quot; domain</measure>
    <time_frame>1 month</time_frame>
    <description>Increment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSFI (Female Sexual Function Index) questionnaire all domains</measure>
    <time_frame>1 month</time_frame>
    <description>Increment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSDS-R (Female Sexual Distress Scale- Revised) score</measure>
    <time_frame>1 month</time_frame>
    <description>Decline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Menopause</condition>
  <condition>Sexual Desire Disorder</condition>
  <condition>Hypoactive Sexual Desire Disorder</condition>
  <arm_group>
    <arm_group_label>Vaginal progesterone 8%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaginal progesterone application 8%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral multivitamin supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vaginal progesterone 8%</intervention_name>
    <description>vaginal self application</description>
    <arm_group_label>Vaginal progesterone 8%</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Menopausal status

          -  Sexually active

        Exclusion Criteria:

          -  Medical history of chronic psychiatric disease

          -  Medical conditions associated with female sexual dysfunction; cardiovascular disease,
             uncontrolled chronic HT (hypertension) ,DM (diabetes mellitus), History of gynecologic
             surgery, female gynecological cancer ( breast, ovarian, uterine, cervical)

          -  Medications associated with female sexual dysfunction; Antidepressants opiates, beta
             blockers, Antiepileptics ( gabapentin, topiramate,phenytoin) benzodiazepines
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serdar G Aydin, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bezmialem Üniversitesi Tıp Fakültesi Hastanesi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ayşe G Karasu, M.D</last_name>
    <phone>5365144142</phone>
    <email>agokmenkarasu@bezmialem.edu.tr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bezmialem Vakif University</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayşe F Karasu</last_name>
      <phone>5365144142</phone>
      <email>agokmenkarasu@bezmialem.edu.tr</email>
    </contact>
    <contact_backup>
      <last_name>Ayşe F Karasu, Türkiye</last_name>
      <phone>5365144142</phone>
      <phone_ext>Karasu</phone_ext>
      <email>agokmenkarasu@bezmialem.edu.tr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Prasad A, Mumford SL, Buck Louis GM, Ahrens KA, Sjaarda LA, Schliep KC, Perkins NJ, Kissell KA, Wactawski-Wende J, Schisterman EF. Sexual activity, endogenous reproductive hormones and ovulation in premenopausal women. Horm Behav. 2014 Jul;66(2):330-8. doi: 10.1016/j.yhbeh.2014.06.012. Epub 2014 Jun 20.</citation>
    <PMID>24954690</PMID>
  </reference>
  <reference>
    <citation>Brown SG, Calibuso MJ, Roedl AL. Women's sexuality, well-being, and the menstrual cycle: methodological issues and their interrelationships. Arch Sex Behav. 2011 Aug;40(4):755-65. doi: 10.1007/s10508-010-9630-3. Epub 2010 May 13.</citation>
    <PMID>20464468</PMID>
  </reference>
  <reference>
    <citation>Gangestad SW, Thornhill R. Human oestrus. Proc Biol Sci. 2008 May 7;275(1638):991-1000. doi: 10.1098/rspb.2007.1425. Review.</citation>
    <PMID>18252670</PMID>
  </reference>
  <reference>
    <citation>Grebe NM, Gangestad SW, Garver-Apgar CE, Thornhill R. Women's luteal-phase sexual proceptivity and the functions of extended sexuality. Psychol Sci. 2013 Oct;24(10):2106-10. doi: 10.1177/0956797613485965. Epub 2013 Aug 21.</citation>
    <PMID>23965377</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2016</study_first_submitted>
  <study_first_submitted_qc>November 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2016</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoactive sexual desire disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Hypokinesia</mesh_term>
    <mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

